Dan Zandberg, MD
Hematology & Oncology · Baltimore, MDNPI 1912184763
Payments from drug & device makers
Across 426 payments — averaging $23,183 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$7.8M
- GSK$483K
- AstraZeneca$436K
- E.r. Squibb & Sons, L.L.C.$418K
- Macrogenics, Inc.$157K
- AVEO Pharmaceuticals, Inc.$151K
- plus $432K from 15 others
Across 2 payments — averaging $478.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$957
What the payments were for
- Consulting fees$16,84573%
- Speaking & faculty fees$2,0669%
- Travel & lodging$3,33314%
- Food & beverage$7703%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 103 | $7,799,076 |
| GSK | 122 | $482,586 |
| AstraZeneca | 6 | $435,958 |
| E.r. Squibb & Sons, L.L.C. | 10 | $418,012 |
| Macrogenics, Inc. | 36 | $157,475 |
| AVEO Pharmaceuticals, Inc. | 22 | $151,182 |
| Janssen Research & Development, LLC | 37 | $116,979 |
| EMD Serono, Inc. | 1 | $81,632 |
| Incyte Corporation | 60 | $42,223 |
| Bristol Myers Squibb | 3 | $39,242 |
| Regeneron | 5 | $34,570 |
| Verastem, Inc. | 3 | $25,949 |
| Exelixis Inc. | 3 | $24,752 |
| Pfizer | 1 | $23,850 |
| Novartis | 3 | $20,219 |
| Genentech, Inc. | 5 | $10,638 |
| Eli Lilly | 1 | $6,642 |
| Secura Bio, Inc. | 1 | $3,015 |
| Coherus Oncology, Inc. | 2 | $1,246 |
| Blueprint Medicines Corporation | 1 | $866 |
| Seagen Inc. | 1 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$3,228
How this compares
$9,876,158 in reported general payments places this provider in the 95th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 26 | $632,725 |
| Prochlorperazine Maleate | 43 | $1,417 |
| Ondansetron Hcl | 33 | $563 |
| Oxycodone Hcl | 14 | $540 |
| Ondansetron OdtOndansetron | 14 | $304 |
| Levothyroxine Sodium | 30 | $229 |
| Gabapentin | 17 | $131 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Baltimore
- Ani BalmanoukianBaltimore$6.6M
- Mark MarkowskiBaltimore$5.9M
- Ivana GojoBaltimore$5M
- Suman RaoBaltimore$4.2M
- Patrick FordeBaltimore$4.1M
- Mehmet KocogluBaltimore$3.5M
- Noah HahnBaltimore$3.4M
- Seung Tae LeeBaltimore$2.7M
- Maria BaerBaltimore$2.6M
- Kevin ChenBaltimore$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.